• news.cision.com/
  • Sanofi-Aventis Norge AS/
  • -- Results of a Head-to-Head Study Comparing Two of the Most Widely Used Chemotherapy Agents in Breast Cancer Published in the Journal of Clinical Oncology --
Norsk

-- Results of a Head-to-Head Study Comparing Two of the Most Widely Used Chemotherapy Agents in Breast Cancer Published in the Journal of Clinical Oncology --

Report this content

Paris – August 18, 2005 – The sanofi-aventis Group announced today that the Journal of Clinical Oncology has published the results of a phase III trial which demonstrate that treatment with TAXOTERE (docetaxel) Injection Concentrate significantly improved overall survival and median time to disease progression compared with paclitaxel in women with advanced breast cancer whose disease had progressed after previous treatment with an anthracycline-based therapy. The study shows a statistically significant median overall survival of 15.4 months for TAXOTERE versus 12.7 months for paclitaxel (HR, 1.41; 95% CI, 1.15 to 1.73; p=0.03).1 TAXOTERE and paclitaxel are agents in a class known as taxanes, which are commonly used to treat women with advanced breast cancer.2

Hele pressemeldingen i pdf-format ligger vedlagt.

Dokumenter og linker